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Abstract
Background: Epidemiological studies have shown a J- or U-shaped relation between alcohol and type 2 diabetes and
coronary heart disease (CHD). The underlying mechanisms are not clear. The aim was to examine the association between
alcohol intake and diabetes and intermediate CHD risk factors in relation to selected ADH and ALDH gene variants.
Methodology/Principal Findings: Cross-sectional study including 6,405 Northern European men and women aged 30–60
years from the general population of Copenhagen, Denmark. Data were collected with self-administered questionnaires, a
physical examination, a 2 hour oral glucose tolerance test, and various blood tests. J shaped associations were observed
between alcohol and diabetes, metabolic syndrome (MS), systolic and diastolic blood pressure, triglyceride, total cholesterol,
and total homocysteine. Positive associations were observed with insulin sensitivity and HDL cholesterol, and a negative
association with insulin release. Only a few of the selected ADH and ALDH gene variants was observed to have an effect. The
ADH1c (rs1693482) fast metabolizing CC genotype was associated with an increased risk of impaired glucose tolerance
(IGT)/diabetes compared to the CT and TT genotypes. Significant interactions were observed between alcohol and ADH1b
(rs1229984) with respect to LDL and between alcohol and ALDH2 (rs886205) with respect to IGT/diabetes.
Conclusions/Significance: The selected ADH and ALDH gene variants had only minor effects, and did not seem to markedly
modify the health effects of alcohol drinking. The observed statistical significant associations would not be significant, if
corrected for multiple testing.
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Introduction
Epidemiological studies have consistently shown that light to
moderate drinkers compared to abstention are at lower risk of type
2 diabetes (T2D) and coronary heart disease (CHD) whereas
heavy and excessive drinkers are at increased risk or has a risk
equal to that of non-consumers [1–7]. The potential mechanisms
of this so-called U or J-shaped association include beneficial effects
on insulin sensitivity, high density lipoprotein (HDL) and low
density lipoprotein (LDL) cholesterol, blood pressure and
triglycerides [8–11]. However it has been argued that the observed
inverse association between moderate alcohol consumption and
diabetes and CHD is attributed to confounding factors such as a
healthy lifestyle, misclassification of former alcoholics, or to
constituents of alcohol other than ethanol, such as the antioxidants
in grapes [12].
Alcohol is primarily metabolized in the liver. The major
enzymes involved are alcohol dehydrogenase (ADH) and aldehyde
dehydrogenase (ALDH). Firstly ethanol is oxidized to acetalde-
hyde in a reversible reaction catalyzed by the class I ADH
isoenzymes (ADH1a, ADH1b, ADH1c) located in the cytosol of
hepatocytes. Functional relevant polymorphisms are found in the
genes encoding ADH1b and ADH1c, affecting ethanol degrada-
tion rates and alcohol intake in white populations [13–16]. These
polymorphisms have been widely studied and related to various
disease outcomes both in Asian and white populations [17–19].
Acetaldehyde is then oxidized to acetate and water in a non-
reversible reaction catalyzed by the mitochondrial class II ALDH2
[20,21]. The ALDH2 gene is also polymorphic and contains an
inactive variant unable to metabolize acetaldehyde resulting in the
Oriental flushing syndrome [22,23]. However, this variant is
nearly absent in white populations [24]. Another less studied
polymorphism in the promoter region of ALDH2 gene has been
reported in white populations, which may influence ALDH2
activity through effects on transcriptional activity [25,26]. In
addition, various single nucleotide polymorphisms (SNP’s) in other
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metabolism of alcohol in the stomach mucosa and the class I
ALDH1b1 (previously named as ALDHX and ALDH5) may also
play a role, although their functional relevance and clinical
importance is unknown [17,27].
Variations in the alcohol metabolizing genes may help to clarify
whether the association is causal, since it is less likely that an
individual’s genetic composition is associated with confounding
factors as genotypes are distributed randomly and thus mimic a
randomized trial (a principle referred to as Mendelian Random-
ization) [28]. Moreover a gene-environment interaction effect will
only be observed if ethanol is responsible for the association.
The aim of the study was to examine the association between
weekly alcohol intake and diabetes and CHD risk factors in
relation to various ADH and ALDH gene variants.
Materials and Methods
Ethics statement
Informed written consent was obtained from all participants
before participation. The study was approved by the Ethical
Committees of Copenhagen and was in accordance with the
principle of the Helsinki Declaration II.
Study population
The current study is based on the Inter99 study, a population-
based randomized controlled trial, investigating the effect of
lifestyle intervention (smoking cessation, increased physical
activity, and healthier dietary habits) on CVD. The present study
was focused on the baseline data before any intervention had been
offered. Data were collected with self-administered questionnaires,
a physical examination, a 2 hour oral glucose tolerance test and
various blood tests. Details on the study population, health
examination, and the intervention program have been described
elsewhere [29]. Briefly, the Inter99 study population were
residents in the southern part of the former Copenhagen County.
An age- and sex-stratified random sample of 13,016 men and
women born in 1939–40, 1944–45, 1949–50, 1954–55, 1959–60,
1964–65, and 1969–70 was drawn from the Danish Civil
Registration System and invited to participate in a health
examination during 1999–2001, so that they were aged 30, 35,
40, 45, 50, 55, 60, and 65 years on the day of the examination. A
total of 12,934 were eligible for invitation. The baseline
participation rate was 52.5% (n=6,784). Information on current
and former nationalities of participants as well as their parents was
obtained from Statistics Denmark and from the self-administered
questionnaire. A Northern European origin was defined as a
Danish, Norwegian, Swedish, Icelandic, or Faroese nationality. A
non-Northern European origin was defined as nationalities other
than the above mentioned. Both current and potential former
nationalities of participants and their parents were considered.
Only participants with a Northern European origin (Denmark,
Norway, Sweden, Iceland, and Faroe Islands) were included in the
current study (n=6,405).
Glucose tolerance status
All participants without known diabetes underwent a 2 hour
standardized 75 g oral glucose tolerance test (OGTT) in the
morning after an overnight fast. Plasma glucose, serum insulin,
and serum C-peptide were measured at time (t) 0, 30, and 120 min
during the OGTT. Glucose concentrations were analyzed by
hexokinase/glucose-6-phosphate dehydrogenase assay (Boehringer
Mannheim, Germany). Insulin and C-peptide levels were
measured by a fluoroimmunoassay technique (Dako Diagnostics
Ltd., UK). Glucose tolerance status was defined according to
WHO diagnostic criteria 1999 [30]. Impaired fasting glucose
(IFG) was defined as: fasting plasma glucose $6.1 mmol/l and
2 hour plasma glucose ,7.8 mmol/l. Impaired glucose tolerance
(IGT) was defined as: fasting plasma glucose ,7.0 mmol/l, and
2 hour plasma glucose $7.8 mmol/l and ,11.1 mmol/l. Diabe-
tes was defined as: fasting plasma glucose $7.0 and 2 hour plasma
glucose $11.1 mmol/l. IGT and diabetes were combined in the
statistical analyses to increase power.
Surrogate measures of Insulin release and insulin
sensitivity
Estimates of insulin release and insulin sensitivity were estimated
using both homeostasis model assessment (HOMA) based upon
fasting circulating glucose and insulin levels [31].
Alcohol
The information on alcohol drinking was obtained from the self-
administered questionnaire. The on average amount and type
(beer, wine, dessert wine, spirits) of alcoholic beverage consumed
per week in the last 12 months were recorded. One beer, one glass
of wine, or one glass of spirit was approximated to one standard
drink defined as 1.5 cl or 12 g of pure ethanol. Total weekly
alcohol intake was calculated as the sum of weekly intakes of beer,
wine, dessert wine and spirits. For the analyses of main effects,
alcohol consumption was categorized in eight categories: 0, .0–2,
.2–4, .4–7, .7–14, .14–21, .21–35, .35 standard drinks per
week. For the analyses of interaction effects, weekly alcohol intake
was categorized in three groups: non-drinkers (0 standard drinks),
light/moderate drinkers (.0–14 for women; .0–21 for men),
heavy drinkers (.14 for women; .21 for men).
ADH and ALDH gene variants
Based on previous reports on potential causal associations with
disease outcomes, the following single nucleotide polymorphisms
(SNPs) were examined: ADH1b Arg47His (rs1229984), ADH1c
Arg271Gln (rs1693482) [15], ADH7 (rs1573496) [17], ALDH2 59-
UTR A-357G (rs886205) [25,26,32], ALDH1b1 Ala69Val (rs2228093)
[33,34], and ALDH1b1 Arg90Leu (rs2073478) [33,34]. The SNP’s
were genotyped by KBiosciences allele-specific PCR (KASPar)
(KBiosciences, Hoddesdon, UK). All genotyping success rates were
above 96.6% with a mismatch rate of 0.0% for the above mentioned
SNP’s in 384 duplicate samples. Rs1229984 and rs886205 deviated
significantly from the Hardy-Weinberg equilibrium (p,0.001 and
p=0.025, respectively).
Biological risk factors and metabolic syndrome
The physical examination included measurement of weight
(wearing light clothes and no shoes) and height, waist circumfer-
ence (in standing position at umbilical level), hip circumference,
and systolic and diastolic blood pressure (measured twice in a
sitting position after 5 minutes rest). Fasting triglyceride, choles-
terols, homocysteine, urine albumin, and urine creatine were
measured by standard techniques. Metabolic syndrome (MS) was
defined according to the WHO diagnostic criteria 1999 with
modifications as suggested by EGIR [30,35]. MS was defined as
insulin resistance, diabetes, impaired glucose regulation, or
impaired fasting glucose in combination with two or more of the
following risk factor components: dyslipidemia, hypertension,
obesity or microalbuminuria. Insulin resistance was defined as
fasting plasma insulin in the upper 25% quartile ($50.0 pmol/l) of
the non-diabetic population [35]. Glucose tolerance status was
defined above. Dyslipidemia was defined as high triglycerides
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and ,1.0 mmol/l (women)). Hypertension was defined as high
systolic blood pressure ($140 mmHg) and/or high diastolic blood
pressure ($90 mmHg). Obesity was defined as high BMI
($30 kg/m
2) and/or high waist-hip ratio (.0.90 (men) and
.0.85 (women)). Microalbuminuria was defined as albumin-
creatinine ratio $30 mg/g.
The self-administered questionnaire
The self-administered questionnaire provided information on
potential confounders such as socioeconomic factors, smoking
status, physical activity, general dietary habits, menopause status
and use of hormone replacement therapy. Smoking status was
recorded as never smokers, ex-smokers, occasional smokers
(,gram tobacco per day), and daily smokers. Total physical
activity was calculated on the basis of a question on commuting
physical activity and a question on leisure time physical activity
including walking, gardening etc. and grouped into four categories
as described by von Huth et al. [36]. Based on responses to
qualitative questions about intake of fruit, vegetables, fish, and
saturated fat, a dietary quality score was calculated as described by
Toft et al. [37]. Social class was defined on the basis of questions
regarding number of years of vocational training and employment
status and categorised into five classes as described previously [38].
Postmenopausal hormone replacement therapy use was recorded
in three categories: 1) premenopausal, 2) postmenopausal ever
user, and 3) postmenopausal never user.
Statistical analyses
Statistics were computed with the statistical program SAS,
version 9.1 (SAS Institute Inc, Cary, NC, USA). All p values
reported are two-tailed and statistical significance was defined as
p,0.05.
All continuous outcome variables were visually tested for
approximation to the normal distribution by histograms and
QQ-plots. HDL, triglyceride, homocysteine, HOMA-is, and
HOMA-%B were log-transformed to achieve a normal distribu-
tion. Crude associations with continuous outcomes were examined
by means and geometric means and tested for significant
differences by one-way analysis of variance (F test). Crude
association with dichotomous outcomes were examined in simple
frequency tables and tested for significant differences by the chi-
square test. Adjusted associations were evaluated in linear and
logistic regression models using the PROC GLM (continuous
outcomes) and the PROC GENMOD (dichotomous outcomes)
procedures. Effects were reported as odds ratios (OR) and b
coefficients with 95% confidence intervals (95% CI). b coefficients
from models with log-transformed outcomes were back-trans-
formed and reported as % with 95 CI. Regression models were
adjusted for sex, age, BMI, dietary habits, physical activity,
smoking status, socioeconomic status, and postmenopausal
hormone replacement therapy use. Interaction effects were
examined and evaluated in the regression models by including a
product term. F-tests and Wald’s tests for single parameters were
used to test for significance in the regression analyses. Reported p
values were not corrected for multiple testing. However, the large
number of tests was taken into account in the interpretation of
results. Persons receiving blood pressure and/or lipid lowering
drugs were excluded in models including blood pressure and/or
lipids. Known diabetics were excluded in analyses including
HOMA estimates, since they may receive medication. Models with
homocysteine included only half of the population, since only a
sub-sample of the study population were a priori selected for
homocysteine determination [39].
Results
General characteristics of the study population
The current study population consisted of 3.099 (48.4%) men
and 3.306 (51.6%) women with a mean age of 46.3 (range: 29.7–
61.3) years. The median weekly alcohol intake was 6.5 (range: 0–
330) standard drinks including 578 (9.4%) abstainers. A total of
375 (6.2%) participants had diabetes and 1.409 (24.4%) were
characterized with MS. The frequency of the ADH and ALDH
minor alleles were: 0.02 (rs1229984), 0.42 (rs1693482), 0.11
(rs1573496), 0.17 (rs886205), 0.12 (rs2228093), and 0.40
(rs2073478). Further characteristics of the study population are
given in table 1.
Association of alcohol intake with diabetes and
intermediate CHD risk factors
Alcohol consumption was significantly associated with the risk of
diabetes as well as MS in a J or U shaped manner. Abstainers and
excessive drinkers (.35 standard drinks per week) had the highest
risks, whereas light drinkers (.2–4 standard drinks per week) had
the lowest risk (table S1). Alcohol was also significantly associated
with surrogate measures of insulin sensitivity and insulin release.
An increasing alcohol intake was associated with increasing insulin
sensitivity and decreasing insulin release when applying the
HOMA model (table S1). Significant associations were also found
Table 1. Characteristics of the Inter99 study population.
Characteristic
Men (% (n)) 48.4 (3099)
Age (mean (sd)) 46.26 (7.91)
Standard drinks per week (median (min, max)) 6.5 (0, 330)
Abstainers (% (n)) 9.4 (578)
Binge drinkers (% (n)) 37.1 (2225)
Daily smoking (% (n)) 35.7 (2274)
BMI$30 kg/m
2 (% (n)) 17.6 (1124)
Very low physical activity (% (n)) 12.0 (720)
Less healthy dietary habits (% (n)) 16.0 (990)
Lowest social class (% (n)) 3.6 (212)
Postmenopausal women (% (n))
a 52.9 (1709)
Hormone replacement therapy (% (n))
a 16.9 (546)
Diabetes
Impaired glucose tolerance (% (n)) 11.4 (690)
Known diabetes (% (n)) 4.1 (251)
Screen-detected diabetes (% (n)) 2.1 (124)
Metabolic syndrome (% (n)) 24.4 (1409)
Systolic blood pressure (mean (sd)) 129.31 (17.05)
Diastolic blood pressure (mean (sd)) 81.77 (11.01)
Hdl cholesterol (mean (sd)) 1.4 4(0.40)
Ldl cholesterol (mean (sd)) 3.51 (0.96)
Total cholesterol (mean (sd)) 5.54 (1.08)
Triglyceride (mean (sd)) 1.33 (1.31)
Homocysteine (mean (sd)) 9.00 (4.49)
Data are % (n), mean (sd), or median (min, max). Ntotal may differ due to missing
information on some of the variables.
aAmong women.
doi:10.1371/journal.pone.0011735.t001
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The associations between alcohol intake and blood pressure,
triglyceride, total cholesterol, and total homocysteine were J
shaped, and a positive association was observed with HDL
cholesterol (table S2). No significant interaction effects were
observed between alcohol and sex with respect to the various
outcomes (range of p values: 0.072–0.839).
Associations of ADH and ALDH gene variants with
diabetes and intermediate CHD risk factors
The ADH1c (rs1693482) polymorphism was significantly
associated with diabetes/IGT both in crude analyses (table 2)
and after adjustment for potential confounders (p=0.011) in a co-
dominant model. The fast metabolizing CC genotype were
associated with an increased risk of IGT/diabetes compared to
CT and TT genotypes although no clear dose-response relation-
ship was observed (table 2). The ADH1b fast metabolizing AA
genotype also seemed to increase the risk of IGT/diabetes
compared to the GG and GA genotypes. However, only very
few subjects (n=9) were AA homozygous and the results were not
statistically significant (table 2). In addition the ADH1b and
ADH1c fast metabolising alleles seemed to be associated with
decreased insulin sensitivity and increased insulin release (table 2).
However none of the associations were statistically significant.
Moreover, the ADH1b (rs1229984) and ALDH1b1 (rs2073478)
variants also seemed to be associated with HDL and LDL,
respectively, in crude analyses (table 2, table 3), but not after
adjustment for confounders (data not shown).
Interaction effects between alcohol and ADH and ALDH
gene variants
In crude analyses, interaction effects were observed between
alcohol and ADH1b (rs1229984) with respect to LDL (pinteraction
=0.009) and between alcohol and ADH7 (rs1573496) with respect
Table 2. Association between ADH and ALDH gene variants and diabetes related phenotypes.
n Insulin sensitivity Insulin release Metabolic syndrome IGT/diabetes
(geometric mean (95% CI)) (geometric mean (95% CI)) (% (n)) (% (n))
ncases=1409 ncases=1065
ADH1b (rs1229984)
GG, slow 5744 0.82 (0.81;0.83) 52.05 (51.24;53.87) 24.0 (1253) 17.1 (942)
GA 230 0.78 (0.72;0.85) 52.53 (48.64;56.74) 26.1 (55) 17.0 (36)
AA, fast 9 0.61 (0.33;1.10) 61.36 (34.26;109.89) 22.2 (2)
p=0.291 p=0.733 p=0.486 p=0.92
ADH1c (rs1693482)
CC, fast 2016 0.80 (0.80;0.83) 52.36 (50.96;53.79) 24.6 (457) 19.4 (373)
CT 2886 0.82 (0.80;0.84) 52.07 (50.94;53.22) 23.6 (614) 15.6 (428)
TT, slow 1031 0.83 (0.80;0.87) 51.45 (49.60;53.37) 23.8 (222) 17.3 (172)
p=0.229 p=0.755 p=0.712 P=0.003
ADH7 (rs1573496)
CC 4881 0.82 (0.81;0.84) 51.98 (51.10;52.87) 24.2 (1073) 17.3 (807)
GC 1169 0.79 (0.76;0.83) 52.40 (50.62;54.24) 24.3 (260) 17.7 (198)
GG 72 0.73 (0.62;0.87) 59.30 (51.86;67.81) 25.4 (16) 16.7 (11)
p=0.125 P=0.168 p=0.969 P=0.943
ALDH2 (rs886205)
TT 4075 0.82 (0.80;0.83) 52.26 (51.29;53.25) 24.6 (910) 17.6 (685)
CT 1709 0.82 (0.79;0.85) 51.55 (50.12;53.03) 23.1 (357) 16.3 (266)
CC 144 0.88 (0.79;0.98) 49.15 (44.36;54.47) 19.7 (26) 18.0 (25)
p=0.389 p=0.394 p=0.258 P=0.512
ALDH1b1 (rs2228093)
CC 4586 0.82 (0.80;0.84) 51.93 (51.02;52.86) 23.9 (995) 17.2 (754)
CT 1303 0.81 (0.78;0.84) 52.74 (51.05;54.47) 24.7 (292) 17.2 (214)
TT 87 0.91 (0.80;1.04) 45.20 (40.26;50.74) 23.4 (18) 16.7 (14)
p=0.263 p=0.068 p=0.834 P=0.992
ALDH1b1 (rs2073478)
TT 2142 0.82 (0.79;0.84) 52.02 (50.67;53.41) 24.7 (478) 17.7 (361)
GT 2869 0.82 (0.80;0.84) 51.93 (50.81;53.07) 23.6 (615) 16.9 (463)
GG 930 0.81 (0.77;0.84) 53.10 (51.04;55.25) 24.5 (209) 17.1 (153)
p=0.909 p=0.605 p=0.689 P=0.746
N are the maximum number of participants in each category. N may be lower due to missing information on some variables. Data are geometric means with 95%
confidence intervals (CI) or % (n). P values are F tests or Chi-square test.
doi:10.1371/journal.pone.0011735.t002
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the interaction between alcohol and the ADH1b (rs1229984)
variant with respect to LDL remained statistically significant after
adjustment for confounders (table 4). Heavy drinking was
associated with lower LDL levels among participants with the
fast metabolizing A allele (table 4). Moreover, a significant
interaction effect was observed between ALDH2 (rs886205) and
IGT/diabetes in the adjusted model (table 5).
Discussion
In this study we examined the association between alcohol and
diabetes and intermediate CHD risk factors in relation to selected
ADH and ALDH gene variants in an adult general population sample.
We observed a strong association between alcohol intake and
diabetes, MS and several CHD risk factors. The ADH and ALDH
gene variants on the other hand had only minor effects, and did not
seem to markedly modify the health effects of alcohol drinking.
Our results confirm previous studies showing a U- or J-shaped
relation between alcohol and type 2 diabetes and CHD [1–7].
Meta analyses have shown that light-moderate alcohol consump-
tion is associated with a protective effect in the order of 30–40%
with respect to type 2 diabetes and 20–30% with respect to CHD
[2,6,7,40].
The finding of positive association with surrogate measures of
insulin sensitivity and a negative relation with insulin release,
suggest that the J-shaped relation may be explained by a
beneficial effect of moderate alcohol intake on the insulin
Table 3. Association between ADH and ALDH gene variants and CHD related phenotypes.
n
Systolic blood
pressure
Diastolic blood
pressure Hdl cholesterol
Ldl
cholesterol Triglyceride Homocysteine
(mmHg) (mmHg) (mmol/l) (mmol/l) (mmol/l) (mmol/l)
(Mean (95% CI)) (Mean (95% CI))
(Geometric mean
(95% CI))
(Mean (95%
CI))
(Geometric mean
(95% CI))
(Geometric mean
(95% CI))
ADH1b (rs1229984)
GG, slow 5744 129.3 (128.8;129.8) 81.7 (81.4;82.0) 1.39 (1.38;1.40) 3.51 (3.48;3.54) 1.12 (1.10;1.13) 8.42 (8.30;8.53)
GA 230 128.8 (126.6;131.1) 82.4 (80.8;84.0) 1.37 (1.33;1.42) 3.42 (3.29;5.54) 1.16 (1.08;1.25) 8.24 (7.77;8.74)
AA, fast 9 128.7 (115.8;141.5) 83.9 (77.5;90.3) 1.08 (0.92;1.26) 4.52 (2.82;4.22) 1.49 (1.05;2.12) 7.18 (4.46;11.55)
p=0.932 p=0.560 p=0.018 p=0.382 p=0.142 p=0.604
ADH1c (rs1693482)
CC, fast 2016 129.6 (128.8;130.4) 81.9 (81.4;82.4) 1.39 (1.37;1.40) 3.53 (3.48;3.57) 1.14 (1.11;1.17) 8.51 (8.33;8.70)
CT 2886 129.2 (128.6;129.9) 81.7 (81.2;82.1) 1.38 (1.37;1.40) 3.49 (3.45;3.52) 1.11 (1.09;1.13) 8.38 (8.22,8.54)
TT, slow 1031 128.6 (127.5;129.7) 81.7 (81.0;82.4) 1.40 (1.37;1.42) 3.51 (3.45;3.57) 1.10 (1.06;1.13) 8.29 (8.03;8.57)
p=0.321 p=0.808 p=0.624 p=0.353 p=0.096 p=0.382
ADH7 (rs1573496)
CC 4881 129.4 (128.9;129.9) 81.9 (81.5;82.2) 1.39 (1.38;1.40) 3.51 (3.49;3.54) 1.12 (1.11;1.14) 8.35 (8.24;8.48)
GC 1169 129.3 (128.2;130.3) 81.6 (80.9;82.3) 1.39 (1.37;1.41) 3.50 3.45;3.56) 1.11 (1.07;1.14) 8.57 (8.31,8.83)
GG 72 125.7 (121.5;130.0) 79.4 (76.9;81.9) 1.38 (1.29;1.48) 3.36 (3.12;3.59) 1.12 (0.99;1.26) 9.18 (7.56;11.14)
p=0.227 p=0.177 p=0.978 p=0.368 p=0.669 p=0.141
ALDH2 (rs886205)
TT 4075 129.5 (128.9;130.0) 81.9 (81.5;82.3) 1.39 (1.37;1.40) 3.50 (3.47;3.53) 1.12 (1.10;1.14) 8.45 (8.32;8.58)
CT 1709 129.0 (128.1;129.8) 81.4 (80.9;82.0) 1.39 (1.37;1.41) 3.53 (3.48;3.57) 1.12 (1.10;1.15) 8.31 (8.10;8.52)
CC 144 130.1 (127.0;133.3) 81.7 (79.8;83.5) 1.40 (1.33;1.46) 3.40 (3.26;3.54) 1.09 (1.00;1.20) 8.24 (7.70;8.83)
p=0.551 p=0.339 p=0.941 p=0.298 p=0.793 p=0.498
ALDH1b1 (rs2228093)
CC 4586 129.3 (128.8;129.9) 81.8 (81.4;82.1) 1.39 (1.38;1.40) 3.51 (3.48;3.53) 1.12 (1.10;1.13) 8.44 (8.31;8.57)
CT 1303 129.4 (128.4;130.3) 81.8 (81.1;82.4) 1.38 (1.36;1.40) 3.52 (3.46;3.57) 1.12 (1.09;1.16) 8.32 (8.10;8.55)
TT 87 129.5 (125.9;133.2) 81.7 (79.4;84.0) 1.45 (1.36;1.55) 3.41 (3.20;3.62) 1.11 (0.99;1.24) 8.43 (7.41;9.59)
p=0.993 p=0.999 p=0.244 p=0.602 p=0.929 p=0.684
ALDH1b1 (rs2073478)
TT 2142 129.4 (128.6;130.2) 81.7 (81.2;82.2) 1.38 (1.37;1.40) 3.50 (3.46;3.55) 1.12 (1.08;1.15) 8.52 (8.33;8.72)
GT 2869 129.6 (128.9;130.2) 81.9 (81.5;82.3) 1.38 (1.37;1.40) 3.54 (3.51;3.58) 1.11 (1.09;1.14) 8.39 (8.24;8.54)
GG 930 128.3 (127.1;129.5) 81.3 (80.6;82.1) 1.39 (1.36;1.41) 3.43 (3.36;3.49) 1.12 (1.08;1.16) 8.23 (7.96;8.51)
p=0.185 p=0.424 p=0.940 p=0.007 p=0.948 p=0.203
N are the maximum number of participants in each category. N may be lower due to missing information on some variables. Data are geometric mean or mean with
95% confidence intervals (CI). P values are F tests.
doi:10.1371/journal.pone.0011735.t003
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Genotype
Alcohol
drinking n Systolic Diastolic Hdl Ldl Triglyceride Homocysteine
blood pressure blood pressure cholesterol cholesterol
(mmHg) (mmHg) (mmol/l) (mmol/l) (mmol/l) (mmol/l)
(b (95% CI)) (b (95% CI)) (% (95% CI)) (b (95% CI)) (% (95% CI)) (% (95% CI))
ADH1b
(rs1229984)
G G ( s l o w ) N o n 4 9 3 00000 0
GG (slow) Light/
moderate
4140 20.35 (21.99;1.29) 20.75 (21.81;0.32) 8.15 (5.67;10.70) 0.00 (20.09;0.09) 22.20 (26.82;2.65) 25.81
(210.44;20.95)
GG (slow) Heavy 915 4.31(2.38;6.23) 1.59 (0.34;2.84) 21.93 (18.61;25.34) 20.01 (20.12;0.09) 3.10 (22.66;9.19) 23.44 (29.10;2.58)
GA and AA
(fast)
Non 37 21.37 (26.95;4.21) 0.29 (23.32;3.91) 3.28 (25.02;12.30) 0.04 (20.29;0.37) 3.23 (213.29;22.90) 25.59 (224.14;17.50)
GA and AA
(fast)
Light/
moderate
161 21.16 (24.29;1.97) 20.42 (22.45;1.61) 9.63 (4.88;14.58) 20.14 (20.31;0.04) 23.29 (211.80;6.04) 27.57 (216.19;1.94)
GA and AA
(fast)
Heavy 23 1.19 (26.01;8.39) 21.09 (25.75;3.58) 14.32 (3.50;26.29) 20.69 (21.09;20.30) 27.68 (3.80;57.06) 212.46 (228.97;7.87)
Pinteraction=0.836 Pinteraction=0.483 Pinteraction=0.287 Pinteraction=0.017 Pinteraction=0.132 Pinteraction=0.766
ADH1c
(rs1693482)
CC (fast) Non 170 00000 0
CC (fast) Light/
moderate
1479 0.30 (22.41;3.00) 20.05 (21.80;1.71) 4.77 (0.79;8.90) 20.03 (20.18;0.12) 0.77 (27.04;9.23) 27.52 (215.25;0.91)
CC (fast) Heavy 282 4.16 (0.93;7.38) 2.95 (0.85;5.04) 19.02 (13.59;24.71) 20.03 (20.21;0.15) 3.43 (2615;13.99) 20.88 (210.85;10.21)
CT Non 274 0.52 (22.77;3.80) 0.89 (21.25;3.02) 22.19 (26.66;2.49) 20.09 (20.28;0.09) 21.87 (210.97;8.15) 24.93 (214.19;5.34)
CT Light/
moderate
2057 20.13 (22.80;2.53) 20.24 (21.97;1.49) 5.34 (1.39;9.43) 20.06 (20.21;0.09) 23.90 (211.25;4.05) 27.79 (215.37;0.48)
CT Heavy 458 5.10 (2.09;8.11) 1.87 (20.09;3.83) 16.97 (12.00;22.15) 20.13 (20.30;0.04) 4.72 (24.32;14.63) 27.80 (216.36;1.65)
TT (slow) Non 85 0.55 (23.83;4.94) 0.99 (21.86;3.83) 27.14
(212.81;21.10)
0.02 (20.23;0.27) 1.51 (210.97;15.74) 24.37 (217.02;10.22)
TT (slow) Light/
moderate
721 20.17 (23.01;2.68) 0.22 (21.62;2.07) 5.31 (1.10;9.70) 20.06 (20.23;0.10) 23.62 (211.47;4.92) 210.31
(218.18;21.68)
TT (slow) Heavy 191 4.62 (1.10;8.14) 1.81 (20.48;4.09) 19.30 (13.44;25.46) 20.03 (20.23;0.17) 2.05 (28.09;13.31) 210.67 (220.38;0.22)
Pinteraction=0.878 Pinteraction=0.566 Pinteraction=0.131 Pinteraction=0.692 Pinteraction=0.619 Pinteraction=0.515
ADH7
(rs1573496)
C C N o n 4 2 1 00000 0
CC Light/
moderate
3507 20.13 (21.92;1.57) 20.33 (21.50;0.83) 6.54 (3.87;9.27) 20.02 (20.12;0.08) 22.03 (27.08;3.29) 27.07
(211.98;21.88)
CC Heavy 781 4.43 (2.33;6.54) 2.15 (0.78;3.51) 19.58 (16.05;23.22) 20.02 (20.13;0.10) 5.85 (20.56;12.68) 24.15 (210.17;2.28)
GC and GG Non 121 20.76 (24.20;2.68) 20.05 (22.28;2.18) 20.87 (25.61:4–10) 20.07 (20.26;0.13) 24.73 (213.98;5.52) 21.38 (211.64;10.06)
GC and GG Light/
moderate
878 20.43 (22.47;1.61) 20.72 (22.04;0.60) 6.47 (3.44;9.60) 0.01 (20.11;0.12) 21.41 (27.18;4.72) 21.89 (27.79;4.39)
GC and GG Heavy 195 4.82 (1.90;7.75) 0.87 (21.03;2.77) 20.49 (15.49;25.69) 20.11 (20.27;0.06) 20.77 (29.16;8.40) 23.94 (212.70;5.70)
Pinteraction=0.853 Pinteraction=0.597 Pinteraction=0.872 Pinteraction=0.314 Pinteraction=0.219 Pinteraction=0.344
ALDH2
(rs886205)
T T N o n 3 4 5 00000 0
TT Light/
moderate
2953 0.40 (21.54;2.35) 20.59 (21.84;0.67) 7.45 (4.54;10.45) 20.03 (20.13;0.08) 23.39 (28.78;2.31) 25.21 (210.74;0.66)
TT Heavy 644 5.63 (3.35;7.91) 1.79 (0.31;3.26) 20.57 (16.72;24.55) 20.08 (20.20;0.05) 0.76 (25.81;7.84) 23.07 (29.68;4.04)
CT and CC Non 179 2.34 (20.82;5.50) 0.01 (22.03;2.06) 20.78 (25.12;3.75) 20.08 (20.26;0.10) 24.81 (213.27;4.47) 2.32 (27.12;12.73)
CT and CC Light/
moderate
1305 0.40 (21.65;2.46) 20.98 (22.31;0.35) 8.41 (5.29;11.63) 20.01 (20.13;0.11) 24.63 (210.26;1.36) 25.37 (211.22;0.86)
CT and CC Heavy 287 3.55 (0.84;6.27) 1.05 (20.70;2.81) 22.20 (17.52;27.06) 0.00 (20.16;0.15) 24.63 (210.26;1.36) 22.45 (210.90;6.81)
Pinteraction=0.080 Pinteraction=0.843 Pinteraction=0.743 Pinteraction=0.412 Pinteraction=0.224 Pinteraction=0.889
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release perhaps caused by a toxic alcohol effect on the pancreatic
b cells. However the insulin release may also decrease with
increasing alcohol intake due to lower demands caused by the
increasing sensitivity. In this context, misclassification of alcohol
exposure should also be considered (see below).
Furthermore, our results support previous findings of beneficial
effects of alcohol drinking on insulin sensitivity and HDL
cholesterol levels [9–11]. Also in accordance with our results
elevated blood pressure, triglyceride, total and LDL cholesterol in
heavy-excessive drinkers have been reported previously [8,9].
Studies on the relationship between total alcohol intake and
circulating homocysteine levels have been inconsistent, but several
studies have shown a lowering effect of beer drinking on plasma
homocysteine concentrations, which has also been reported
previously for this cohort [38].
In the current study we observed significant associations between
ADH1c (rs1693482) and IGT/diabetes (co-dominant model). The fast
metabolizing C allele was related to a higher risk of IGT/diabetes.
This is supportive ofa protective roleofalcohol, since individualswith
genotypes coding for fast alcohol degradation have lower blood
alcohol concentrations. Moreover, the ADH1c C allele has been
associated with a lower alcohol intake also contributing to lower
blood alcohol concentrations [13,14]. Beulens et al. also reported in a
nested case-control study of 1.023 white men and women with
incident diabetes and 1.382 controls that the ADH1c genotype
modified the association between alcohol consumption and diabetes.
In this study the slow metabolizing allele seemed to attenuate the
lower risk of diabetes among moderate to heavy drinkers [41].
Although we did observe an association between the ADH1c
(rs1693482) variant and IGT/diabetes as well as insulin sensitivity,
the direction was opposite, and we could not confirm the results.
However in accordance with our results, Hines et al. showed in a
nested case-control study of 1166 U.S. male physicians (396 patients
and 777 controls) that the slow oxidizing ADH1c allele is associated
with reduced risk of myocardial infarct in moderate drinkers [42].
This has been confirmed in other populations [43,44]. In addition an
interaction between ADH1c and the level of alcohol consumption in
relation to HDL has been reported in several studies [42,45] although
not in all [43,46].
The ADH1b rs1229984 GG slow genotype has been associated
with elevated blood pressure, triglycerides, and uric acid in one
Genotype
Alcohol
drinking n Systolic Diastolic Hdl Ldl Triglyceride Homocysteine
blood pressure blood pressure cholesterol cholesterol
(mmHg) (mmHg) (mmol/l) (mmol/l) (mmol/l) (mmol/l)
(b (95% CI)) (b (95% CI)) (% (95% CI)) (b (95% CI)) (% (95% CI)) (% (95% CI))
ALDH1b1
(rs2228093)
C C N o n 4 1 1 00000 0
CC Light/
moderate
3290 20.19 (22.00;1.63) 20.68 (21.85;0.50) 7.67 (4.95;10.46) 0.02 (20.08;0.12) 25.14 (210.06;0.05) 23.57 (28.90;2.08)
CC Heavy 715 3.48 (1.34;5.63) 1.20 (20.19;2.59) 21.02 (17.38;24.78) 20.02 (20.14;0.10) 20.04 (26.20;6.52) 22.26 (28.71;4.64)
CT and TT Non 114 20.01 (23.57;3.56) 20.32 (22.63;1.99) 22.45 (27.30;2.64) 0.09 (20.11;0.29) 28.13 (217.36;2.14) 5.26 (25.24;16.93)
CT and TT Light/
moderate
1003 20.84 (22.85;1.18) 20.99 (22.29;0.31) 6.95 (3.94;10.04) 0.00 (20.11;0.12) 23.09 (28.68;2.83) 24.95 (210.73;1.21)
CT and TT Heavy 225 6.12 (3.34;8.90) 2.17 (0.37;3.97) 20.56 (15.81;25.51) 0.01 (20.15;0.16) 5.49 (22.97;14.69) 20.23 (28.76;9.09)
Pinteraction=0.066 Pinteraction=0.364 Pinteraction=0.782 Pinteraction=0.570 Pinteraction=0.105 Pinteraction=0.423
ALDH1b1
(rs2073478)
T T N o n 1 9 0 00000 0
TT Light/
moderate
1545 20.18 (22.81;2.46) 21.20 (22.90;0.50) 5.96 (2.06;10.02) 0.00 (20.15;0.15) 21.91 (29.28;6.07) 23.78 (211.34;4.42)
TT Heavy 326 3.22 (0.10;6.35) 0.95 (21.07;2.98) 18.97 (13.76;24.42) 20.08 (20.26;0.10) 0.83 (28.14;10.67) 22.80 (211.83;7.15)
GT Non 254 0.41 (22.85;3.68) 0.16 (21.95;2.27) 22.58 (26.97;2.02) 0.00 (20.18;0.19) 0.05 (29.11;10.13) 21.41 (210.78;8.95)
GT Light/
moderate
2066 20.37 (22.96;2.23) 20.84 (22.52;0.84) 6.39 (2.52;10.41) 0.02 (20.12;0.17 23.89 (211.02;3.82) 26.72 (213.95;1.11)
GT Heavy 442 4.95 (2.01;7.90) 1.54 (20.37;3.44) 18.79 (13.87;23.93) 20.01 (20.18;0.16) 5.82 (23.10;15.57) 24.68 (213.24;4.74)
GG Non 85 21.52 (25.93;2.89) 21.81 (24.66;1.05) 21.90 (27.95;4.55) 20.05 (20.30;0.20) 23.89 (215.82;9.71) 2.71 (210.68;18.10)
GG Light/
moderate
656 21.14 (23.95;1.67) 21.18 (23.00;0.63) 5.71 (1.54;10.04) 20.08 (20.24;0.07) 20.15 (28.16;8.56) 29.13
(216.74;20.82)
GG Heavy 161 3.87 (0.22;7.52) 0.75 (21.61;3.12) 21.53 (15.34;28.04) 20.02 (20.23;0.18) 0.86 (29.52;12.43) 25.22 (215.30;6.06)
Pinteraction=0.673 Pinteraction=0.804 Pinteraction=0.593 Pinteraction=0.745 Pinteraction=0.282 Pinteraction=0.837
N are the maximum number of participants in each category. N may be lower due to missing information on some variables. Data are b coefficients with 95%
confidence intervals (CI) from adjusted regression analyses. The category ‘‘wildtype non drinkers’’ was set as the joint reference group. b coefficients from models with
log-transformed outcomes were back-transformed and reported as % with 95% CI. All p values are F tests.
doi:10.1371/journal.pone.0011735.t004
Table 4. Cont.
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Genotype Alcohol drinking n Insulin sensitivity Insulin release Metabolic syndrome IGT/diabetes
(% (95% CI)) (% (95% CI)) (OR (95% CI)) (OR (95% CI))
ncases=1409 ncases=1065
ADH1b (rs1229984)
GG (slow) Non 493 0 0 1 1
GG (slow) Light/moderate 4140 13.11 (6.67;19.94) 212.66 (217.42;27.63) 0.63 (0.47;0.85) 0.67 (0.50;0.88)
GG (slow) Heavy 915 22.66 (14.45;31.47) 225.28 (230.06;220.17) 0.93 (0.66;1.31) 1.05 (0.76;1.45)
GA and AA (fast) Non 37 211.60 (227.68;8.04) 2.35 (215.48;23.95) 1.31 (0.48;3.56) 0.76 (0.26;2.22)
GA and AA (fast) Light/moderate 161 14.55 (2.39;28.16) 214.14 (222.86;24.43) 0.60 (0.33;1.08) 0.63 (0.35;1.13)
GA and AA (fast) Heavy 23 8.74 (214.75;38.72) 213.94 (231.78;8.55) 0.35 (0.08;1.45) 0.90 (0.28;2.91)
Pinteraction=0.353 Pinteraction=0.449 Pinteraction=0.326 Pinteraction=0.929
ADH1c (rs1693482)
CC (fast) Non 170 0 0 1 1
CC (fast) Light/moderate 1479 10.37 (0.14;21.66) 28.43 (216.56;0.49) 0.76 (0.46;1.26) 0.75 (0.48;1.19)
CC (fast) Heavy 282 20.06 (6,84;34.91) 220.32 (228.78;210.93) 1.21 (0.67;2.18) 1.08 (0.64;1.85)
CT Non 274 23.42 (214.16;8.66) 7.40 (24.03;20.18) 1.45 (0.80;2.63) 0.95 (0.55;1.64)
CT Light/moderate 2057 14.44 (3.97;25.96) 29.50 (217.43;20.80) 0.72 (0.44;1.19) 0.53 (0.34;0.83)
CT Heavy 458 21.83 (9.28;35.81) 221.31 (229.07;212.71) 1.04 (0.60;1.80) 1.02 (0.62;1.69)
TT (slow) Non 85 20.37 (215.01;16.81) 3.77 (210.83;20.76) 1.11 (0.51;2.44) 0.65 (0.29;1.43)
TT (slow) Light/moderate 721 13.78 (2.69;26.06) 29.77 (218.19;20.48) 0.84 (0.49;1.42) 0.70 (0.43;1.15)
TT (slow) Heavy 191 22.27 (7.67;38.85) 224.79 (233.38;215.08) 1.10 (0.59;2.07) 0.94 (0.53;1.68)
Pinteraction=0.855 Pinteraction=0.632 Pinteraction=0.614 Pinteraction=0.315
ADH7 (rs1573496)
CC Non 421 0 0 1 1
CC Light/moderate 3507 13.56 (6.55;21.04) 212.42 (217.59;26.92) 0.63 (0.46;0.88) 0.78 (0.57;1.06)
CC Heavy 781 20.02 (11.34;29.38) 223.08 (228.41;217.36) 1.03 (0.71;1.50) 1.19 (0.83;1.70)
GC and GG Non 121 22.80 (214.07;9.95) 1.59 (29.68;14.28) 1.07 (0.58;1.97) 1.46 (0.83;2.56)
GC and GG Light/moderate 878 9.94 (2.26;18.20) 210.36 (216.35;23.93) 0.72 (0.50;1.05) 0.82 (0.57;1.18)
GC and GG Heavy 195 23.49 (11.10;37.26) 228.41 (235.28;220.80) 0.74 (0.44;1.26) 1.25 (0.77;2.02)
Pinteraction=0.526 Pinteraction=0.180 Pinteraction=0.227 Pinteraction=0.577
ALDH2 (rs886205)
TT Non 345 0 0 1 1
TT Light/moderate 2953 18.59 (10.67;27.06) 214.73 (220.15;28.94) 0.53 (0.37;0.74) 0.54 (0.39;0.74)
TT Heavy 644 25.56 (15.76;36.18) 225.56 (231.09;219.59) 0.78 (0.52;1.16) 0.83 (0.58;1.20)
CT and CC Non 179 7.60 (23.86;20.44) 24.99 (214.67;5.79) 0.59 (0.33;1.05) 0.43 (0.24;0.76)
CT and CC Light/moderate 1305 17.35 (9.06;26.27) 214.79 (220.52;28.64) 0.43 (0.30;0.62) 0.49 (0.35;0.69)
CT and CC Heavy 287 31.78 (19.56;45.25) 229.09 (235.36;222.22) 0.62 (0.38;1.00) 0.79 (0.51;1.22)
Pinteraction=0.224 Pinteraction=0.440 Pinteraction=0.591 Pinteraction=0.038
ALDH1b1 (rs2228093)
CC Non 411 0 0 1 1
CC Light/moderate 3290 15.14 (7.98;22.78) 213.69 (218.81;28.23) 0.59 (0.42;0.81) 0.63 (0.46;0.86)
CC Heavy 715 24.91 (15.71;34.84) 225.64 (230.87;220.02) 0.81 (0.55;1.19) 0.99 (0.70;1.42)
CT and TT Non 114 0.79 (211.56;14.86) 24.00 (215.24;8.73) 1.06 (0.56;2.01) 0.84 (0.45;1.57)
CT and TT Light/moderate 1003 13.48 (5.66;21.87) 212.88 (218.61;26.74) 0.67 (0.46;0.97) 0.84 (0.45;1.57)
CT and TT Heavy 225 19.21 (7.81 (31.81) 225.16 (231.99;217.64) 1.14 (0.70;1.85) 1.11 (0.70;1.75)
Pinteraction=0.756 Pinteraction=0.754 Pinteraction=0.673 Pinteraction=0.699
ALDH1b1 (rs2073478)
TT Non 190 0 0 1 1
TT Light/moderate 1545 16.98 (6.57;28.41) 215.55 (222.75;27.67) 0.56 (0.35;0.88) 0.75 (0.48;1.19)
TT Heavy 326 29.77 (16.08;45.07) 230.03 (237.10;222.16) 0.77 (0.45;1.32) 1.03 (0.61;1.74)
GT Non 254 1.17 (29.87;13.57) 22.45 (212.65;8.94) 0.86 (0.48;1.53) 0.98 (0.56;1.71)
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no relation to HDL [46]. We observed a decreased fasting serum
LDL level among heavy drinkers with the intermediate/fast
ADH1b (rs1229984) GA/AA genotype.
An interaction effect was also observed between ALDH2
(rs886205) and IGT/diabetes in the current study. The relation-
ship of this ALDH2 variant as well as the ADH7 and ALDH1b1
variants with diabetes and CHD related phenotypes have not been
studied previously, except from a previous study (n=1,216) from
our group [13]. In this study we observed an association between
the ALDH1B1 (rs2228093) gene variant and diastolic blood
pressure, which was not confirmed in the current study. Besides
that we did not observe any effects of ADH1b (rs1229984), ADH1c
(rs1693482), ALDH1b1 (rs2228093, rs2073478), and ALDH2
(rs886205) with respect to blood pressure, cholesterols, and
triglyceride in this previous study [13]. Studies on the inactive
ALDH2 Asian variant have found no association with neither
cholesterols [48] nor blood pressure [49,50].
Taken as a whole the studies on the effects of genetic variation
in ADH and ALDH on the risk of type 2 diabetes and CHD have
been inconsistent. One explanation could be that drinking patterns
and levels of intake differ between Danes and e.g. the US
population. Moreover, our results with the genetic variants would
not be significant after correction for multiple testing, and we
believe that many of the inconsistencies between studies may be
due to chance findings, although we cannot exclude that they are
real. Nonetheless, these results do not exclude a causal relationship
between alcohol and diabetes and CHD, but they do suggest that
the influence of genetic variation in the alcohol metabolizing
enzymes is relatively small.
Previously, we showed that the ADH1b (rs1229984), ADH1c
(rs1693482) and ALDH1b1 (rs2228093) genotypes is associated
with amount of alcohol intake, which may have interfered with
the principles of Mendelian randomization and influenced the
results. Individuals with ADH1b and ADH1c slow metabolizing
genotypes were drinking more [51]. Thus ADH1b and ADH1c
slow metabolizers have higher blood ethanol concentrations
due to both the lower activity of the enzyme and to a higher
alcohol intake. Both effects stem directly from the genotype and
cannot be separated. If ethanol is responsible for the adverse/
beneficial effects of alcohol drinking the observed associations
would have been intensified. However, if a more downstream
metabolite e.g. acetaldehyde is responsible for the effects of
alcohol, the observed associations may have been attenuated
towards the null value due to opposing effects of enzyme
activity and alcohol intake (low ADH enzyme activity results in
low acetaldehyde peak levels and a high alcohol intake results
in high acetaldehyde levels). The ALDH1b1 (rs2228093)
genotypes have also been shown to influence alcohol drinking
habits, but the effects of this polymorphism on enzyme activity
is unknown.
Several other potential limitations of the study should be
considered. Firstly, despite the relatively large number of
participants in the current study, it is possible that the study
may have missed important effects of the genetic variants due to
low statistical power. In contrast, a large number of statistical
tests have been performed in this study which increases the risk of
chance findings. The observed statistical significant associations
involving the ADH and ALDH gene variants would not be
significant after correction for multiple testing. Moreover,
rs1229984 and rs886205 were not in Hardy-Weinberg equilib-
rium. However the prevalence of the gene variants was similar to
other studies on European populations, suggesting that this has
perhaps happened by chance [14,26,32,34,52]. Also, among 384
replicate samples, we found no genotype errors for the two SNPs.
In addition, the alcohol intake was estimated on the basis of a
self-administered questionnaire and not by an objective method.
Due to social desirability bias the participants may have
underreported their actual intake. However, the ranking of
participants were probably quite accurate, as total weekly alcohol
intake as assessed by this method in another population-based
study has previously been found to be positively associated with
markers of high alcohol intake [13,53]. However, the J-shape
might also be explained by the possibility that some previous or
current heavy drinkers are misclassified as non-drinkers. Finally,
the cross-sectional study design may not allow us to draw firm
conclusions about the causal direction of associations between
alcohol and e.g. diabetes. Thus, we cannot exclude the possibility
that persons with diabetes have changed their alcohol intake due
to the disease. However, associations with genetic variants may
favour a causal relationship, since an individual’s genetic
composition does not change over time and is less likely to be
associated with confounding factors.
In conclusion, strong associations between weekly alcohol intake
and diabetes, MS and several intermediate CHD risk factors were
observed. The ADH and ALDH gene variants on the other hand
had only minor effects, and did not seem to modify the health
effects of alcohol drinking greatly in this study.
Genotype Alcohol drinking n Insulin sensitivity Insulin release Metabolic syndrome IGT/diabetes
(% (95% CI)) (% (95% CI)) (OR (95% CI)) (OR (95% CI))
ncases=1409 ncases=1065
GT Light/moderate 2066 16.75 (6.50;27.98) 215.18 (222.31;27.38) 0.54 (0.35;0.85) 0.67 (0.43;1.06)
GT Heavy 442 22.26 (10.09;35.77) 225.49 (232.60;217.64) 0.86 (0.48;1.53) 1.11 (0.67;1.83)
GG Non 85 5.49 (29.94;23.57) 26.90 (219.95;8.29) 0.94 (0.44;2.02) 1.40 (0.68;2.86)
GG Light/moderate 656 11.93 (1.33;23.64) 212.45 (220.40;23.71) 0.64 (0.39;1.05) 0.77 (0.47;1.26)
GG Heavy 161 22.61 (7.69;39.59) 224.27 (233.10;214.27) 0.72 (0.38;1.37) 1.32 (0.72;2.40)
Pinteraction=0.574 Pinteraction=0.460 Pinteraction=0.745 Pinteraction=0.855
N are the maximum number of participants in each category. N may be lower due to missing information on some variables. Data are b coefficients or odds ratios (OR)
with 95% confidence intervals (CI) from adjusted regression analyses. The category ‘‘wildtype non drinkers’’ was set as the joint reference group. b coefficients from
models with log-transformed outcomes were back-transformed and reported as % with 95% CI. All p values are F tests.
doi:10.1371/journal.pone.0011735.t005
Table 5. Cont.
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